Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486492 | 0.84 | AGXT (0.33) | CA1CA2TAAR1CYP1A2ALDH1A1 | |
| SCHEMBL16969082 | 0.81 | IDO1 (0.39) | CA1CA2TAAR1ALDH1A1TP53 | |
| SCHEMBL15548429 | 0.78 | EPHX2 (0.39) | LMNAALDH1A1TSHR | |
| SCHEMBL5952624 | 0.77 | TRPA1 (0.39) | LIPECA1CA2TAAR1SLC6A2 | |
| SCHEMBL25377641 | 0.77 | CA1 (0.46) | LIPECA1CA2TAAR1SLC6A2 | |
| SCHEMBL5838358 | 0.75 | ALDH1A1 (0.35) | CYP2C19LMNAALDH1A1HIF1ATSHR | |
| SCHEMBL7648550 | 0.75 | NPC1 (0.44) | LMNAALDH1A1 | |
| SCHEMBL16178580 | 0.75 | CA1 (0.44) | CA1CA2ALDH1A1 | |
| SCHEMBL1774449 | 0.73 | LTA4H (0.40) | CYP2C19CYP1A2CYP2C9LMNACYP2D6 | |
| SCHEMBL15229065 | 0.73 | MAOA (0.35) | CYP2D6ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | Kynan Duke IP, LLC (US) | 2025-11-04 | — | — | US | claimed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | claimed |
| CN-115485259-A | Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof | 凯楠公爵IP有限责任公司 | 2022-12-16 | — | — | CN | claimed |
| WO-2021127743-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2021-07-01 | — | — | WO | claimed |
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | Kynan Duke IP, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4638440-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-115151553-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-114514228-B | Pyridinamide derivatives as agricultural fungicides | 环球化学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4312557-B1 | PHYTOSTEROL-BASED AGRICULTURAL COMPOSITION AND THEIR USE | ELICIT PLANT (FR) | 2025-01-01 | — | — | EP | disclosed |
| EP-4349170-B1 | PHYTOSTEROL-BASED AGRICULTURAL COMPOSITION AND THEIR USE | ELICIT PLANT (FR) | 2024-12-04 | — | — | EP | disclosed |
| US-20110282090-A1 | PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL | UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | LIPE 2062/4885CA1 4871/4885CA2 4824/4885 |
| US-20110282090-A1 | PROCESS FOR PREPARING BORONIC ACIDS AND ESTERS IN THE PRESENCE OF MAGNESIUM METAL | ME1, MEN1, CYP2B6 | LIPE 1717/4885CA1 900/4885CA2 268/4885 |
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | LIPE 202/4885CA1 3573/4885CA2 1689/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | LIPE 1270/4885CA1 4251/4885CA2 1618/4885 |
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | CYP8B1, HSD11B1, HSD11B2 | LIPE 346/4885CA1 4441/4885CA2 3977/4885 |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | CYP8B1, HSD11B1, HSD11B2 | LIPE 346/4885CA1 4441/4885CA2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.